Pharmacogenetic Study of Drugs Affecting Mycobacterium tuberculosis.

Samira ShabaniPoopak FarniaJalaledin GhanaviAli Akbar VelayatiParissa Farnia

Published in: International journal of mycobacteriology (2024)

Genetic variations in NAT2 and SLCO1B1 can affect the metabolism of INH and RIF, respectively. A better understanding of the pharmacogenetic profile in the study population may facilitate the design of more personalized and effective TB treatment strategies. Further research is needed to directly correlate these genetic markers with clinical outcomes in TB patients.

Keyphrases

mycobacterium tuberculosis
end stage renal disease
pulmonary tuberculosis
newly diagnosed
ejection fraction
genome wide
chronic kidney disease
peritoneal dialysis
gene expression
prognostic factors
copy number